BioSpace News Archive

Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic Cystic Fibrosis patients, especially those with nonsense mutations, are at increased risk of severe illness WALTHAM, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mut

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a producer of refined cannabis ingredients for the pharmaceutical, medical, nutraceutical, and cosmetic industries, provides an update on our operations, the first closing of a loan agreement and the measures we have taken in response to the current COVID-19 global pandemic.

Astaxanthin from Haematococcus pluvialis microalgae has demonstrated wide-ranging effects on immune system modulation as evidenced in 28 pre-clinical as well as five human clinical trials.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that the U.S. Patent & Trademark Office has issued a patent protecting its proprietary implant surface technology.

Foldax® announced today that it has completed initial enrollment in its early feasibility study (EFS) for the Tria LifePolymer™ heart valve.

Titan Medical Inc. announce today that it has entered into definitive agreements with institutional investors that provide for the purchase and sale of 7,000,000 common shares of the Comp

Castle Creek Biosciences, Inc., a privately held, late-stage gene therapy company, announced that it has received a new investment of $75 million to support the advancement of its clinical development pipeline.

Tecsys Inc., an industry-leading supply chain management software company, announces that despite ongoing global disruptions due to the spread of COVID-19, the company is well-equipped to uphold comprehensive support and services for its end-to-end supply chain execution software through its multi-tiered customer care and support teams.

- Multiple antibodies identified that neutralize SARS-CoV-2 - Phase 1/2 clinical testing planned for this summer

Forge Therapeutics, Inc. (Forge) announced today that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa.